Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Citations Search

Sort By:

J. Biomol. Scr. 9, 3-11. A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput Streptococcus pneumoniae transcription/translation screen. 2004

Pratt, S.D., David, C.A., Black-Schaefer, C., Dandliker, P.J., Xuei, X., Warrior, U., Burns, D.J., Zhong, P., Cao, Z., Saiki, A.Y.C., Lerner, C.G., Chovan, L.E., Soni, N.B., Nilius, A.M., Wagenaar, F.L., Merta, P.J., Traphagen, L. and Beutel, B.A.

Notes: Several different sequences from a S. pneumoniae pA promoter region were cloned into the pSP-luc+ vector and screened for expression levels in in vitro transcription/translation systems. The RiboMAX™ SP6 Large Scale RNA Production System was used to transcribe luciferase encoding mRNAs.  Luciferase mRNAs and plasmids were used as templates in high throughput inhibition studies in an S. pneumoniae S30 extract described in the paper as well as in Promega’s E. Coli S30 Extract System for Circular DNA and in Rabbit Reticulocyte Lysate. Promega amino acid mixtures were also used in these studies. (3227)

Expand Full Notes »